Immune cells engineered to hunt two targets in brain cancer
NCT ID NCT05168423
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether specially engineered immune cells are safe and feasible for people with a recurring type of brain cancer called glioblastoma. The cells are designed to recognize and attack two specific proteins found on the cancer cells. The study involves 67 participants and focuses on side effects and manufacturing success, not yet on curing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (CART-EGFR-IL13Ra2) that target two proteins on cancer cells
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet on effectiveness. The treatment may cause serious side effects, and many experimental cell therapies fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States